News | June 07, 2012

Life Expectancy Prolonged for Esophageal Cancer Patients

Imaging with PET/CT results in significant effect on patient management

June 7, 2012 – For those with esophageal cancer, initial staging of the disease is of particular importance as it determines whether to opt for a curative treatment or palliative treatment. Research presented in the June issue of The Journal of Nuclear Medicine shows that physicians using positron emission tomography (PET)/computed tomography (CT) can discern incremental staging information about the cancer, which can significantly impact management plans.

In 2012, an estimated 17,500 people will be diagnosed with esophageal cancer and 15,000 will die from the disease. The five-year survival rate for those diagnosed with esophageal cancer without any nodal involvement is 38 percent. However, more than 50 percent of patients have inoperable or metastatic disease when they are initially diagnosed. The five-year survival rate for these individuals ranges from 3.1 to 18.4 percent.

“The superior accuracy of PET/CT compared to conventional staging investigations such as CT allows clinicians to more appropriately choose and more appropriately plan patient therapy. Our data also show that when PET/CT changes management, it does so correctly in almost all cases,” said Thomas Barber, lead author of the study “18F-FDG PET/CT Has a High Impact on Patient Management and Provides Powerful Prognostic Stratification in the Primary Staging of Esophageal Cancer: A Prospective Study with Mature Survival Data.”

The study followed 139 patients with newly diagnosed esophageal cancer between July 2002 and June 2005. Each of the patients underwent conventional staging investigations of CT and/or endoscopic ultrasound, followed by PET/CT. When staging information from the conventional staging investigations differed from the PET/CT information, results were validated by pathologic/intraoperative findings or serial imaging and clinical follow up. The impact on patient management plans was measured by comparing pre-PET/CT plans with post-PET/CT plans. Survival rates of patients were also recorded after five years.

Results of the study show that information gathered from imaging with PET/CT changed the stage group for 59 of the patients (40 percent) and the management plan for 47 of the patients (34 percent). Of the 47 patients who had a change in their management plan, imaging results were validated in 31 patients, and PET/CT correctly changed management in 26 (84 percent) of these. The five-year survival rate for patients with stage IIB-III disease was 38 percent, which is significantly higher than results previously reported (9-34 percent in stage IIB and 6-16 percent in stage III).

“These results demonstrate the power of metabolic imaging with FDG PET/CT when staging esophageal cancer,” Barber noted. “Our results demonstrate that this technique should be incorporated into routine clinical practice.”

Authors of the article “18F-FDG PET/CT Has a High Impact on Patient Management and Provides Powerful Prognostic Stratification in the Primary Staging of Esophageal Cancer: A Prospective Study with Mature Survival Data” include Thomas Barber and Elizabeth Drummond, Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Rodney J. Hicks, Centre for Cancer Imaging, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia; Cuong P. Duong, Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Trevor Leong, Department of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia; and Mathias Bressel, Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

For more information: http://jnm.snmjournals.org

Related Content

Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Radiology Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Brain-scan guided emergency stroke treatment can save more lives
News | Neuro Imaging | January 25, 2018
January 25, 2018 – Advances in brain imagin...
PET Tracer Measures Damage From Multiple Sclerosis in Mouse Models
News | PET Imaging | January 24, 2018
January 24, 2018 — The loss or damage of myelin, a cellular sheath that surrounds and insulates nerves, is the hallma
Overlay Init